Yissum Research Development Company, an arm of Hebrew University of Jerusalem, has entered into an agreement with Aurum Ventures MKI to develop a diagnostic blood test for relapsing-remitting multiple sclerosis (RRMS) and a range of other diseases, which uses differences in DNA from dying cells found in the blood of sick individuals.

TG Therapeutics recently announced the opening of a new clinical trial evaluating TG-1101, its glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (RRMS). The Phase 2 clinical trial, titled “A Placebo-Controlled Multi-Center Phase 2 Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients…

MedDay recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active” progressive MS and those with either relapsing or progressive MS and visual loss, respectively. Data, presented at the recent American…

New data presented by Biogen and AbbVie at the recent 68th annual meeting of the American Academy of Neurology (AAN) showed that Zinbryta (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results — from post-hoc analyses of clinical trials — also offer a better…

Biogen reported new data describing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting of the American Academy of Neurology (AAN). The conference, taking place in Vancouver, Canada, runs through April 21. Tecfidera is an…

PJSC Pharmsynthez, a pharmaceutical company based in Russia, recently announced completed follow-up findings and data analysis from a Phase 2a proof-of-concept clinical trial of its novel therapeutic vaccine Xemys for the treatment of multiple sclerosis (MS). Xemys utilizes Xenetic Biosciences patented ImuXen technology. In the open-label, dose-escalating trial, 20 patients…

The immune system-suppressing multiple sclerosis (MS) drug fingolimod (Gilenya) also has potentially beneficial effects on the nervous system, according to a recent study, “The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.“  The article appeared online March 12 in an early version of the journal …

RedHill Biopharma, Ltd. recently announced promising interim results from its ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy of a fixed dose of RHB-104 as an add-on therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy —…

Researchers at the University of Texas Health Science Center at Houston, in collaboration with various institutions from north America and Europe, found that teriflunomide (Aubagio) is well-tolerated and efficient for long-term treatment of multiple sclerosis (MS). The findings, entitled “Long-term safety and efficacy of teriflunomide,” were…

Damage to the cerebellum in people with multiple sclerosis (MS) is due more to the death of actual nerve cells than the destruction of white matter connections, a new study out of Italy suggests. The article, which challenges previous ideas about how brain damage in MS occurs, is titled “MRI-detectable cortical lesions in the…

Research on a specific type of stem cell found in the placenta, known as decidua-derived mesenchymal stem cells (DMSC), suggests these cells might be the source of future treatments for multiple sclerosis. The report, “Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem…

A new assessment by a European regulatory agency failed to find fingolimod of added benefit to comparator therapies for people with highly active relapsing-remitting multiple sclerosis (RRMS) who have failed to respond to treatment with at least one other disease-modifying drug. Fingolimod (Gilenya), developed as a therapy for multiple sclerosis, has undergone three early benefit assessments since its…

New long-term research indicates that having multiple children does not lessen or otherwise impact disability in women with multiple sclerosis (MS). The study, titled “Offspring Number Does Not Influence Reaching the Disability’s Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study,“ was published in The International Journal…

Dr. Wayne Moore, from the University of British Columbia and the Vancouver General Hospital, will present an overview and analysis of the major histology and pathology aspects that characterize and differentiate relapsing-remitting multiple sclerosis (RRMS) and progressive forms of the disease, primary progressive MS (PPMS) and secondary progressive MS (SPMS).

A Spanish study showed that relapse and remission in multiple sclerosis (MS) states are regulated by small non-coding RNA (sncRNA) molecules in patterns differing between men and women. Scientists have increasingly realized that sncRNAs play an important role in the regulation of gene expression. Various kinds of these RNA molecules, such as…

Elissa Holzman is an MS Health Coach who specializes in nutrition and a healthy lifestyle for supporting those with the disease. She was diagnosed with multiple sclerosis in 2005, which led her to pay closer attention to how she treats her body. In her new column for Multiple Sclerosis News…

Synthetic Biologics, Inc., a clinical stage company focused on the development of therapeutics to protect the microbiome and to target disease-causing pathogens, recently announced disappointing results from an independent third-party analysis of a Phase 2 clinical trial evaluating Trimesta as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women.

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…

New research evaluating fingolimod’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) largely supported its use, finding that the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies. The research article, “Efficacy and Safety of Fingolimod in an Unselected…

Dr. Jerry S. Wolinsky of the University of Texas in Houston, will give the first Kenneth P. Johnson Memorial Lecture at the opening day of the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 in New Orleans, focusing on distinctions between relapsing and progressive disease forms. ACTRIMS…

In a new study entitled “Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis,” a team of researchers discovered a subgroup of secondary progressive multiple sclerosis patients (SPMS) exhibiting the same gene expression response to interferon (IFN) treatment as patients with relapsing-remitting MS…

RedHill Biopharma, Ltd., recently announced the conclusion of the last dosing and patient follow-up visit for its Phase 2a proof-of-concept study to assess the efficacy and safety of the experimental drug RHB-104 as an add-on therapy to interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS).

An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease. The Coral Gables MS Exchange event will be held from 10:30 a.m. to 2:15 p.m. on…

Synthetic Biologics, which specializes in the development of therapies for pathogen-specific diseases, recently announced the publication of new and positive data on results from a Phase 2 clinical trial evaluating the company’s product Trimesta™ as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Professor Rhonda Voskuhl, director of the Multiple Sclerosis Program…

In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosis (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…

In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…

A recently published study in the journal PLOS One reported a new tool to assess risk knowledge in multiple sclerosis (MS) patients. The study was conducted by an international team led by researchers at the University Medical Center Eppendorf in Hamburg, Germany, and is entitled “…

EMD Serono, the U.S. biopharmaceutical division of Merck KGaA, Darmstadt, Germany, recently announced that the results of the 15 year follow-up trial PRISMS-15 (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) evaluating Rebif® (interferon beta-1a), a high-dose, high-frequency interferon beta for the treatment of…

Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…

A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…